Tazemetostat

Generic Name: Tazemetostat

Brand Names: Tazverik

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₄₄N_₄O_₄

CAS Number: 1403254-99-8

Unique Ingredient Identifier: Q40W93WPE1

Background: Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.

Tazemetaostat was granted FDA approval on 23 January 2020.

Indication: Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...

Associated Conditions: Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma

Associated Therapies: -

Clinical Trials

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Lymphoma
Peripheral T Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Interventions: Drug: Tazemetostat
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Cytoxan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Eric Jacobsen, MD

Target Recruit Count: 24

Registration Number: NCT06692452

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Not yet recruiting

Conditions: Refractory Grade 1 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Refractory Grade 2 Follicular Lymphoma
Refractory Grade 3a Follicular Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Epcoritamab
Procedure: Positron Emission Tomography
Drug: Tazemetostat

First Posted Date: 2024-08-28

Last Posted Date: 2024-12-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 33

Registration Number: NCT06575686

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2

Recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Tazemetostat

First Posted Date: 2024-02-05

Last Posted Date: 2024-10-08

Lead Sponsor: Northwestern University

Target Recruit Count: 32

Registration Number: NCT06242834

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Study of Tazemetostat in Lymphoid Malignancies

Phase 1

Not yet recruiting

Conditions: T-cell Lymphoma

Interventions: Drug: Tazemetostat

First Posted Date: 2023-08-09

Last Posted Date: 2024-08-22

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 30

Registration Number: NCT05983965

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2

Recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma
Transformed Non-Hodgkin Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Biological: Tafasitamab
Other: Questionnaire Administration
Drug: Tazemetostat
Drug: Zanubrutinib

First Posted Date: 2023-06-06

Last Posted Date: 2024-10-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 227

Registration Number: NCT05890352

Locations: 🇺🇸
SWOG, Portland, Oregon, United States
🇺🇸
Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
🇺🇸
Saint Joseph Mercy Brighton, Brighton, Michigan, United States

and more 8 locations

A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Phase 2

Recruiting

Conditions: Relapsed/Refractory Lymphoma

Interventions: Drug: tazemetostat
Drug: HMPL-689

First Posted Date: 2023-02-06

Last Posted Date: 2024-10-11

Lead Sponsor: Hutchmed

Target Recruit Count: 140

Registration Number: NCT05713110

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1

Recruiting

Conditions: Refractory Transformed Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

Interventions: Drug: Belinostat
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Pharmacokinetic Study
Procedure: Positron Emission Tomography and Computed Tomography Scan
Drug: Tazemetostat

First Posted Date: 2022-11-25

Last Posted Date: 2024-10-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT05627245

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 7 locations